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Aims: To examine the relationships between glycated haemoglobin (HbA1c) and cardiovascular (CV) events in people beginning insulin in routine clinical
practice in Europe, North America and Asia in a non-interventional study, the Cardiovascular Risk Evaluation in people with Type 2 Diabetes on Insulin
Therapy (CREDIT) study.
Methods: Data on 2999 people were collected prospectively over 4 years from physician reports. The primary outcome was the composite of stroke or
myocardial infarction (MI) or CV-specific death. Events were blindly adjudicated. The relative hazards of CV events were described from Cox proportional
hazardsmodels incorporating patient risk factors, with updated average HbA1c as a time-dependent covariate. The relationship of severe and symptomatic
hypoglycaemia (collected during the 6months before yearly ascertainment) with CV and all-cause mortality was examined.
Results: A total of 147 primary events were accrued during up to 54months of follow-up. In all, 60 CV-specific deaths, 44 non-fatal MIs and 57 non-fatal
strokes occurred, totalling 161 events. There was a significant positive relationship between updated mean HbA1c and primary outcome: hazard ratio (HR)
1.25 [95% confidence interval (CI) 1.12–1.40; p< 0.0001]. CV death [HR 1.31 (95% CI 1.10–1.57); p= 0.0027] and stroke [HR 1.36 (95% CI 1.17–1.59);
p< 0.0001] were both strongly associated with HbA1c, while MI was not [HR 1.05 (95% CI 0.83–1.32)]. One or more severe hypoglycaemic episodes
affected 175 participants, while 1508 participants experienced one or more symptomatic hypoglycaemic events. We found no relationship between
severe/symptomatic hypoglycaemic events and CV-specific/all-cause death.
Conclusions: Ongoing poorer glucose control was associated with CV events; hypoglycaemia was not associated with CV-specific/all-cause death.
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Introduction
The relationship between glycaemic control and cardiovascular
(CV) outcome remains uncertain, with recent randomized tri-
als giving contradictory results [1–4].Observational studies can
provide insights that may be generalized to clinical populations
[5].Post hoc analysis of theACCORD study suggested thatmor-
tality was lowest in those with the best glycated haemoglobin
(HbA1c) values [6], while a further analysis of the same study
suggests that insulin was not detrimental to CV mortality over
5 years [7]. Also controversial is the relationship between hypo-
glycaemia and CV outcomes and death, a relationship that
seems to be weakened by optimization of blood glucose con-
trol [8] and is paralleled by relationships with non-CV disease
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[9], prompting the authors to ask whether it is a marker of vul-
nerability to adverse outcomes rather than having a causal role.
The Cardiovascular Risk Evaluation in people with type 2
Diabetes on InsulinTherapy (CREDIT) study, an international,
4-year, non-interventional, longitudinal study, was designed to
evaluate the relationship between blood glucose control andCV
events in people newly treated with insulin in routine clinical
practice. Other aims were to gain insights into current clini-
cal practice of the use of insulin in people with type 2 diabetes,
and to examine factors predictive of glucose control and body
weight change [10–13]. The study was conceived as an obser-
vational sibling to the ORIGIN interventional trial [14], which
aimed to identify the relationship between very early insulin use
and CV and oncological outcomes, with CREDIT focusing on
outcomes after starting insulin in real-world practice and thus
later in the course of the condition.
In the present paper we describe the association of glycaemic
control with the occurrence of CV events in the CREDIT
study over 4 years. Because of the interest in the potential
relationship between the occurrence of hypoglycaemic events
and CV-specific death or all-cause mortality [6,8,9], we also
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describe the relationship between hypoglycaemic events and
CV-specific death or all-cause mortality. These last analyses
were not part of the original focus of the CREDIT study, but
were included to explore an emerging hypothesis in a novel
dataset.
Materials and Methods
Objectives
The primary aim of the CREDIT study was to identify the
relationship between glycaemic control during follow-up and
the risk ofmajor CVmorbidity andmortality. At the same time,
we examined the relationship between reported hypoglycaemic
episodes and CV or all-cause mortality.
Study Design
The CREDIT study design and participant selection criteria,
as well as the participant baseline characteristics, have been
reported previously [10–13]. In brief, the study involved 314
recruitment centres in 12 countries: 10 in Europe, plus cen-
tres in Canada and Japan. Men and women with type 2 dia-
betes, aged >40 years, who had started any type of insulin ther-
apy within 12months and who had an HbA1c measurement
<3months before starting insulin, were eligible to participate.
As this was a non-interventional study, there was no fixed study
visit schedule, and insulin choice, dosage, titration, medical
costs and concomitant oral-agent therapy were according to
usual local practice. Data were gathered in routine clinical prac-
tice, and the treating physicians were asked to report updated
participant data every 6months. Ethical approval according to
local regulations was obtained for all study sites. The study was
conducted in accordance with standards of data collection for
clinical trials, according to the Declaration of Helsinki. Writ-
ten informed consent was obtained from all participants before
commencement of data collation.
Eligible Population
All people who met the study inclusion criteria and provided
data for assessment of outcome events were eligible for data
analysis.
Outcome Measures
Time-to-event endpoints were calculated from the date of
insulin initiation and were restricted to 54months [i.e. a partic-
ipant who did not experience any event before 1644 days (inclu-
sive) was censored at 1644 days or end of study date (latest date
from date of last contact, death or last visit)].
Occurrence of CV events [myocardial infarction (MI),
stable angina, severe unstable angina leading to hospitaliza-
tion, heart failure leading to hospitalization, stroke, transient
ischaemic attack, peripheral vascular disease, limb amputation,
myocardial revascularization (coronary artery bypass graft-
ing or percutaneous coronary intervention) and peripheral
revascularization (revascularization in any arterial territory
other than coronary arteries)] were to be reported by the
investigator in clinical report forms at 6-month intervals. Sup-
portive documents (e.g. ECG, biochemistry, hospital records,
procedure notes, CT and/or MRI reports, medication charts)
were requested by the study team and the package sent to the
Adjudication Committee.
The CV events were then confirmed by decision of the Adju-
dication Committee (agreement of three reviewers or, if not,
consensus at a formal meeting, using definitions enshrined in
the Adjudication Committee charter). Deaths were adjudicated
as ‘CV’, ‘non-CV’ and ‘cannot classify’, and all other events clas-
sified as ‘event’, ‘no event’ or ‘cannot classify’. Adjudicated CV
death and CV events were used to derive composite outcomes
[major adverse cardiac events (MACE) and MACE+].
The primary aim was to examine the relationship between
HbA1c and CV events. The principal CV event composite
(MACE) was defined as time to the first experience of non-fatal
MI, non-fatal stroke or CV death. The secondary CV event
(MACE+) included severe unstable angina leading to hospi-
talization, heart failure leading to hospitalization, myocardial
revascularization, peripheral revascularization, and lower limb
amputation. We also describe the components of the princi-
pal outcome separately [15]. Analysis using all-cause mortality
rather than CV death was added at editorial request post hoc.
The relationship between reports of severe or symptomatic
hypoglycaemic events and subsequent CV deaths and all-cause
mortality was investigated as a secondary aim as part of the
statistical analysis plan. Symptomatic hypoglycaemia was pre-
defined in the study protocol as any event with clinical symp-
toms resulting in hypoglycaemia, confirmed by plasma glucose
≤3.9mmol/l. Severe hypoglycaemia was defined as an event
that required the assistance of another person and confirmed
by plasma glucose <2.0mmol/l or prompt recovery after oral
carbohydrate, intravenous glucose, or intramuscular glucagon.
Events for the 6months before each visit were ascertained by
patient recall.
Statistical Analysis
The relationship between the hazard of CV events and gly-
caemic control was described using multivariable Cox mod-
els including time-dependent covariate terms [16]. The index
date was the time of insulin initiation. Participant character-
istics other than glycaemic control (such as HbA1c) judged
a priori to be explanatory and likely to affect CV risk were
included as candidate explanatory variables. The number of
candidate explanatory variables that can be fitted without risk-
ing substantial overfitting is limited to p/10, where p is the
number of events. Candidate explanatory variables describing
patient status when starting insulin were age, sex, body mass
index, previous diagnosis of high blood pressure (BP), fam-
ily history of premature CV disease, level of physical activity,
smoking status, macrovascular disease, microvascular disease,
and loge(1+ n) of the number of non-insulin glucose-lowering
therapy treatments. In addition, enabled by the higher num-
ber of events, the following candidate variables were assessed in
the model for the MACE+model: type of first insulin regimen,
time from diagnosis of type 2 diabetes, insulin units per kg,
systolic BP, diastolic BP, heart rate, antihypertensive treatment,
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antiplatelet/anticoagulant treatment, and statin/fibrate treat-
ment. HbA1c was included as a time-dependent explanatory
variable, with themodel updating the overallmeanHbA1c each
year for participants who experienced events that occurred in
that period and for those remaining at risk of events (thus acting
as controls to those events). Updated mean HbA1c of annual
measurements of HbA1c was calculated for each individual
from 1month after insulin initiation to each year of follow-up;
thus, when a patient experienced an event, the mean HbA1c
for the patient up to that point was included automatically by
the model as an explanatory variable, and the corresponding
meanHbA1c for all other subjects who had not yet experienced
an event was included for the calculation of the relationship
between HbA1c level and risk of an event for that individual.
Backward selection was used to remove candidate variables in
turn from the statisticalmodel on the basis of their contribution
to the model, with an inclusion criterion of p< 0.05. Separate
models were derived for MACE and MACE+.
We conducted supportive analyses comparing the updated
mean HbA1c by year (the principal analyses) with models
including the HbA1c for that year alone in nested statisti-
cal models. In addition to this, we examined the relationship
between HbA1c by year and non-fatal MI, non-fatal stroke and
CV-specific death, the individual components of the principal
outcome.
In an exploratory analysis, we examined the relationship
between reported symptomatic or severe hypoglycaemia with
CV-specific death and with all-cause death. Terms identifying
the reporting or otherwise of these events at any time during
follow-up (at the yearly visits) were included in models, along
with the same explanatory variables as in the MACE model.
Results
Population, Glucose Control and Event Rates
Of the 3031 people originally recruited to the CREDIT study
[10–13], 2999 were available for follow-up assessment. The
baseline characteristics of included participants are described
in Table 1. Nine participants did not have any measure of
HbA1c recorded during the study (from starting insulin up
to 54months after starting insulin), with 196 missing at least
one estimation in any year. The median (quartiles 1–3) HbA1c
at year 1 was 7.4 (6.7–8.4)% [57 (50–68)mmol/mol], at year
2 was 7.4 (6.7–8.3)% [57 (50–67)mmol/mol], at year 3 was
7.4 (6.7–8.2)% [57 (50–66)mmol/mol] and at year 4 was 7.3
(6.7–8.2)% [56 (50–66)mmol/mol].
During 54months of potential follow-up, 147 people experi-
enced a first MACE event, and 286 experienced a first MACE+
event. Contributing MACE and MACE+ events are described
in Table 2. The median follow-up between starting insulin and
either a first event or censorship was 4.2 (3.5–4.4) years for
MACE and 4.1 (3.0–4.3) years for MACE+. MACE events were
fairly evenly distributed between the three contributing events
(Table 2). A small number of people with non-fatal MACE
events went on to experience CV death within the 54months
of follow-up. MACE+ events, thus including events defined
by a clinical intervention, amounted to >60% of qualifying
events.
Table 1. Baseline characteristics at the time of starting insulin of people
with type 2 diabetes included in the CREDIT study.
n
Median (interquartile
range) or %
Sex: male 1534 51.2
Age (years) 2999 61 (54–69)
HbA1c 2925 9.3 (8.1–10.7)
Duration of diabetes (years) 2985 9.0 (5.0–14.5)
Previous diagnosis of high BP 2056 68.6
Systolic BP (mmHg) 2749 138 (127–150)
Diastolic BP (mmHg) 2750 80 (72–90)
Body mass index (kg/m2) 2796 28.6 (24.8–32.8)
Physically active, yes 1415 47.4
Smoking status
Never smoked 1667 55.9
Stopped ≥1 year ago 758 25.4
Stopped <1 year ago 104 3.5
Currently smoke 455 15.3
Family history of premature CV disease 757 25.6
≥1 macrovascular disease 1025 34.2
≥1 microvascular disease 2085 69.5
Glucose-lowering therapies 2999 1 (0–2)
≥1 BP-lowering drug 2164 72.2
Antiplatelet/anticoagulant 1231 41.1
Statin/fibrate 1356 45.2
Region
North America 735 24.5
Eastern Europe 647 21.6
Southern Europe 460 15.3
France 511 17.0
Northern Europe 252 8.4
Japan 394 13.1
BP, blood pressure; CV, cardiovascular; HbA1c, glycated haemoglobin.
Physical activity was defined as patient involved in walking, cycling or
gardening for ≥4 h a week.
Multivariable Model
The final statistical model for MACE included age, history or
presence of macrovascular disease when starting insulin, and
previous diagnosis of hypertension (Table 3). Updated average
HbA1c was strongly related to the risk of MACE events [haz-
ard ratio (HR) 1.25 (95% confidence interval (CI) 1.12–1.40);
p< 0.0001]. There was thus a 25% increase in risk for each
1% unit (11mmol/mol) higher average level of HbA1c over
the 54-month period. In the supportive model where the
HbA1c value considered was that in the year of the event,
the magnitude of the relationship with MACE was slightly
reduced, but it was still statistically significant [HR1.23 (95%CI
1.10–1.37); p= 0.0001] and did not differ significantly inmodel
fit (p= 0.43).
In separate models including the same explanatory risk
factors, we examined the relationship between glycaemic
control and stroke, non-fatal MI and CV death, which are
the separate components of MACE (Table 3). Each 1% unit
(11-mmol/mol) or higher average HbA1c was associated
with a 31.2 (9.8–56.7)% increase in the risk of CV death
(p= 0.003) and a 36.3 (16.8–59.1)% increase in the risk of
stroke (p< 0.0001); however, there was no significant relation-
ship between a 1% unit (11mmol/mol) higher HbA1c and
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Table 2. Distribution of first and subsequent composite events and indi-
vidual components over 54months of follow-up.
Events in the
composite
endpoint,
participants, n*
Events by
54months,
participants,
n†
All events
by 54
months,
events, n
MACE 147 147 161
Non-fatal MI 42 42 44
Non-fatal stroke 50 50 57
CV death 55 60 60
MACE+ 286 289 447
Non-fatal MI 37 42 44
Angina hospitalization 18 21 21
Heart failure hospitalization 51 62 78
Non-fatal stroke 47 50 57
Myocardial revascularization 65 101 119
Peripheral revascularization 27 34 46
Lower limb amputation 13 18 22
CV death 34 60 60
CV, cardiovascular; MACE, major adverse cardiovascular event; MI,
myocardial infarction.
*For a MACE+ event, myocardial revascularization and non-fatal MI
occurring the same day are reported for each (six participants).
†The same participant may appear in different categories.
the risk of MI [HR 1.05 (95% CI 0.83–1.32)]. In the post hoc
supportive analysis, the HR for all-cause mortality was 1.15
(95% CI 1.01–1.31; p= 0.030) per unit higher HbA1c.
The final model for MACE+ included sex, physical activ-
ity, macrovascular disease when starting insulin, duration of
diabetes, and antihypertensive therapy when beginning insulin
(Table 3). Updated mean HbA1c was related to the risk of
MACE+ events [HR 1.16 (95% CI 1.07–1.26); p= 0.0003], a
16% increase in risk for each 1% unit (11mmol/mol) increase
in average HbA1c across the 54-month period. In the support-
ive model where the HbA1c value considered in the model was
that in the year of the event, the magnitude of the relationship
withMACEwas slightly reduced, but it was still statistically sig-
nificant [HR 1.14 (95% CI 1.05–1.23); p= 0.0015] and did not
differ significantly in model fit (p= 0.12).
Hypoglycaemia
A total of 175 (6.6%) participants reported at least one severe
hypoglycaemic event, and 1508 (53.7%) reported at least one
symptomatic hypoglycaemic event. Sixty (2.0%) people died
from CV disease and 148 (4.9%) from any cause over 4 years.
We identified no relationship between reported hypoglycaemia
and CV-specific death or all-cause mortality (Table 4).
Discussion
The CREDIT study indentified an important relationship
between glycaemic control and CV risk, describing a clinically
relevant lowering of the hazard of a cluster of CV events with
achievable reductions in HbA1c. These results are broadly
in line with the less-certain effects seen in major random-
ized trials, and they support the conclusion that improved
glycaemic control reduces CV events [6,17,18]. Participants
were newly started on insulin and generally achieved and
maintained reasonable glycaemic control during follow-up
in the study, with median HbA1c of 9.3% (78mmol/mol)
at baseline, declining to 7.4% (57mmol/mol) at the end of
year 1 and 7.3% (56mmol/mol) at the end of year 4. These
circumstances may have improved the power of the study by
excluding both ill people who have reduced HbA1c through
loss of appetite, and thus weight loss, and those stuck at higher
levels of HbA1c because of concomitant disease [6], and thus
judged less suitable for insulin.
The final statistical models for MACE and MACE+ did
not include the specific insulin strategy used when starting
insulin, indicating that for this population in this setting, it
is the lower HbA1c itself (rather than the insulin regimen
used to achieve it) that may be responsible for therapeutic
benefits; however, we cannot exclude the possibility that good
HbA1c levels for those on insulin are related to better glucose
control in past years before insulin was started, and hence
that it is longer-term control that is important, as noted in
the UK Prospective Diabetes Study (UKPDS) [19]. It is also
possible that better blood glucose control is associated with a
better profile of other CV risk factors, although the statistical
uncertainty arising from that putative correlation would make
our fairly powerful findings unlikely, given that the number of
events is not very large.
The PROactive trial found a non-significant 10% reduc-
tion in the primary outcome associated with a 0.5% reduction
in HbA1c achieved with randomization to pioglitazone in a
high-CV-risk populationwith type 2 diabetes but without heart
failure [1]; this outcome is similar to our MACE+ composite.
In the PROactive and CREDIT studies, the benefits of good
HbA1c values with regard to CV risk were greater for MACE
than MACE+ (MACE being driven only by disease status, and
MACE+ also including clinical interventions). The ACCORD
study also found a non-significant 10% reduction in risk of
MACE, coupled with an intensive 1.1% reduction in HbA1c,
but additionally found a nominally statistically significant 22%
increase in CV death [3]. In a recent ACCORD substudy exam-
ining the relationship between glycaemic control and CV risk,
a consistent reduction of CV events associated with better gly-
caemic control was reported [20]. The VADT study reported
a non-significant 12% reduction in the risk of a MACE+ out-
come (which differed in components from that in CREDIT)
associated with a 1.5% reduction in HbA1c [2], a finding that
became significant with a 17% reduction in events at 10 years
in the extension phase [21]. The ADVANCE study saw a 6%
non-significant reduction in MACE events associated with a
0.8% reduction in HbA1c [4].The relationship between HbA1c
reduction andCV events in theUKPDSwas also suggestive, but
uncertain at study end, but again significant at the end of the
extension phase (MI, all-cause mortality), and in study obser-
vational analysis [17,19,22]. Accordingly, the meta-analyses of
these studies also found statistically significant reductions inMI
and overall CV events [18,23].
Our finding that benefits were concentrated on the MACE
components of CV-specific death and non-fatal stroke was
novel and unexpected; conclusions must therefore be drawn
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Table 3. Hazard ratios for the measures retained in the final major adverse cardiovascular event (MACE) and MACE+ models, and for components of
MACE in terms of updated mean glycated haemoglobin per 1% unit.
HR (95% CI) p
MACE
Age at starting insulin (years) 1.035 (1.018–1.053) <0.0001
Previous diagnosis of high BP (yes/no) 1.585 (1.031–2.438) 0.036
≥1 macrovascular disease when starting insulin (yes/no) 2.435 (1.731–3.425) <0.0001
Updated average HbA1c (per 1% unit) 1.250 (1.118–1.398) <0.0001
MACE components (per 1% unit HbA1c)*
CV death 1.312 (1.098–1.567) 0.0027
Stroke 1.363 (1.168–1.591) <0.0001
MI 1.047 (0.833–1.317) 0.693
MACE+
Sex (female vs male) 0.602 (0.470–0.769) <0.0001
Physical activity (yes vs no) 0.732 (0.578–0.928) 0.0101
≥1 macrovascular disease when starting insulin (yes/no) 2.883 (2.205–3.769) <0.0001
Duration of diabetes when starting insulin (years) 1.018 (1.004–1.031) 0.0105
BP-lowering drug when starting insulin (yes/no) 1.652 (1.142–2.388) 0.0076
Antiplatelet/anticoagulant when starting insulin (yes/no) 1.318 (1.008–1.724) 0.0436
Updated mean HbA1c (per 1% unit) 1.161 (1.071–1.259) 0.0003
BP, blood pressure; CI, confidence interval; CV, cardiovascular; HbA1c, glycated haemoglobin; HR, hazard ratio; MACE, major adverse cardiovascular
event; MI, myocardial infarction.
*Including adjustment for age, prior high BP (yes/no) and history or presence of macrovascular disease (yes/no), all when starting insulin.
Table 4. Relationship between reported hypoglycaemia (yes/no) and
cardiovascular-specific or all-cause mortality.
Participants with
death event, n (%)
Event
With
hypoglycaemia
Without
hypoglycaemia
HR
(95% CI)
CV death*
Symptomatic
hypoglycaemia
24 (49.0) 25 (51.0) 0.73 (0.41–1.27)
Severe
hypoglycaemia
3 (7.5) 37 (92.5) 1.10 (0.34–3.57)
All-cause mortality*
Symptomatic
hypoglycaemia
56 (48.3) 60 (51.7) 0.71 (0.49–1.03)
Severe
hypoglycaemia
8 (8.5) 86 (91.5) 1.22 (0.59–2.53)
CI, confidence interval; CV, cardiovascular; HR, hazard ratio.
*Including adjustment for age, prior high BP (yes/no) and history or
presence of macrovascular disease (yes/no), all when starting insulin.
with caution. The findings on CV-specific death were con-
firmed in a post hoc sensitivity analysis for all-cause mortality,
although of course theHR is closer to unitywith the inclusion of
deaths not expected to be influenced by blood glucose control;
however, this also suggests thatwe are not just looking atHbA1c
as amarker of ill health in general.The PROactive study found a
non-significant reduction in non-fatal MI, although it included
silent MI in the outcome [1]. The ACCORD study found a sig-
nificant reduction in non-fatal MI associated with randomiza-
tion to intensiveHbA1c-lowering, although it was coupled with
a significant increase in the risk of CV-specific deaths (rais-
ing the question of competing risks) [3]. While the ADVANCE
study found no benefit in reduced HbA1c on the outcome of
non-fatal MI, neither did it find any in non-fatal stroke [4].
Finally, the VADT study found a non-significant reduction in
non-fatal MI in line with the overall (non-significant) study
estimate of treatment effect [2].The CREDIT study differs from
these other studies in that all patients began insulin, which was
central to the management of their blood glucose. It is pos-
sible that insulin-based strategies are specifically beneficial in
reducing CV-specific death and non-fatal stroke and are not
effective in reducing non-fatal MI; however, a test for hetero-
geneity (systematic difference over and above those expected
through chance alone) indicates that differences in treatment
effect estimates of at least this magnitude may be expected to
occur by chance alone∼16 times in 100; this suggests we should
be cautious about drawing strong conclusions.
We contrasted models in which we used the overall mean
HbA1c and the mean in the previous year as time-dependent
predictors, and found similar results and model fit. This may
be attributable to the relative stability of glycaemic control
over time, but is also supportive of the notion that the degree
of glycaemic control over the proximal period has a useful
predictive effect.
Because of the emerging interest in the potential relation-
ship between hypoglycaemic events and CV-specific death [9],
we included exploratory analyses to assess whether this may be
supported in the CREDIT database. We found no relationship
between severe hypoglycaemia and CV or all-cause mortality,
but with wide CIs. Symptomatic hypoglycaemia was associated
with a non-significant reduction in the risk of death (either
all-cause or CV-specific). Chance is the preferred explanation
of this finding; however, it is plausible that symptomatic hypo-
glycaemia is associated with improved glycaemic control and
thus with an improved outcome. Hypoglycaemia data were col-
lected as symptomatic reports in the previous 6months before
each visit, and thus includes only events within the time period
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and those recalled by the patient; thus, patients who experi-
enced non-symptomatic hypoglycaemia are not included in this
analysis, diluting any effect seen.
The findings contrast with the design of a standard ran-
domized controlled trial, where asymptomatic hypoglycaemic
episodesmay be identified through trial-basedmonitoringwith
correspondingly higher rates of events. It is not clear, how-
ever, whether this can explain the difference in results observed
between previous reports and the CREDIT study, but the
detailed analysis of ACCORD suggested that the association
of severe hypoglycaemia with adverse outcomes was diluted by
the increase in hypoglycaemia with intensification of therapy
[8]. This leads to the conclusion that in non-optimized peo-
ple, hypoglycaemia is a marker of adverse outcomes, but that
the additional hypoglycaemia of optimized therapy must be
less adverse.TheCREDIT population improved glucose control
markedly with the insulin therapy as above, so it is possible we
are looking mainly at the comparatively benign type of hypo-
glycaemia associated with optimization of control with insulin,
rather than the more malign type that marks concomitant ill-
ness [6,9]. Indeed, in the ORIGIN study, conducted in a very
different population to that of CREDIT, and at much tighter
glucose control levels, symptomatic hypoglycaemia was clearly
not associated with adverse CV outcomes [24]. Severe hypogly-
caemia was associated, but weakly, compared with results from
ADVANCE and ACCORD, and at levels compatible with the
wide CIs for hazard we establish with relatively few such events.
The CREDIT study has a number of strengths, including its
rigorous real-world design and independent adjudication ofCV
endpoints. It also has design limitations in addition to those dis-
cussed above. Specifically, there is a trade-off between external
and internal validity in any non-interventional observational
study based on real-world practice, with the former maximized
at the partial expense of the latter. This means that the findings
are not as assured as those from a large, well-designed, ran-
domized study, and it is possible that some other characteristic
confounded with improved glycaemic control was responsible
for the benefits observed. Nevertheless, the real-world design
also enabled the inclusion of a variety of levels of glycaemic
control in individuals over time, resulting in more precision for
estimation. The glycaemic control achieved by participants in
the CREDIT study reflects the best efforts of patients and clin-
icians in normal clinical practice in their choice of therapeutic
agents. This contrasts with randomized trials where patients
and clinicians are largely limited to the imposed experimen-
tal strategies. Evidence such as that from the EXPERIENCE
trial shows that in the real-world setting, where changes can be
made more freely than in conventional trials, larger apparent
treatment effects may be observed for specific therapies than
for treatments used in trials [2,25].
In conclusion, improved glycaemic control was associated
with a clinically useful reduction in CV events in the CREDIT
study over 54 months of follow-up. No difference was observed
in the effects of different insulin regimens, suggesting that good
glycaemic control is important however it is achieved, although
a simple and individualized approach for should be followed
where appropriate.
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